Measurement of Biomarkers of Bone Resorption in Patients With Hormone Sensitive Bone Metastases From Prostate Cancer Treated With Antiandrogen Therapy and Bisphosphonates

University of Aberdeen1 site in 1 country40 target enrollmentSeptember 2010

ConditionsMetastatic Prostate Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Metastatic Prostate Cancer
Sponsor: University of Aberdeen
Enrollment: 40
Locations: 1
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness. Changes in these biomarkers will be correlated with the patient's treatment with antiandrogen therapy and bisphosphonates and the response and/or progression of their cancer. It is hoped that serial measurement of these biomarkers may allow therapeutic monitoring in the future with successful individualisation of bisphosphonate therapy for metastatic prostate cancer.

Registry

clinicaltrials.gov

Start Date

September 2010

End Date

August 2014

Last Updated

10 years ago

Study Type

Observational

Sex

Male